Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
RB101 (N-((R,S)-2-benzyl-3[(S)(2-amino-4-methylthio)butyl dithio]-1-ox-opropyl)-L-phenylalanine benzyl ester) is a recently developed full inhibitor of the enkephalin-catabolizing enzymes able to cross the blood-brain barrier, whereas RB38A ((R)-3-(N-hydroxycarboxamido-2-benzylpropanoyl)-L-phenylalanine) is as potent as RB101 but almost unable to enter the brain. In this study, we have investigated the effects of systemic administration of morphine, RB101 and RB38A on nociception induced by pressure on inflamed peripheral tissues. Antinociceptive test was performed between 4 and 5 days after injection into the rat left hindpaw of Freund's complete adjuvant to produce localized inflammation. Morphine (1, 2 and 4 mg/kg, i.v.) induced antinociception in inflamed paws at all the doses used, and only at the highest dose in non-inflamed paws. RB101 (10 and 20 mg/kg, i.v.) induced an antinociceptive response only in the inflamed paws. RB38A, also induced an antinociceptive effect in the inflamed paws, but only at the highest dose (20 mg/kg, i.v.). The responses induced by morphine and the inhibitors of enkephalin catabolism were antagonized by the systemic administration of naloxone (1 mg/kg) or methylnaloxonium (2 mg/kg) which acts essentially outside the brain. Central injection (i.c.v.) of methylnaloxonium (2 micrograms) blocked the effect of morphine only in non-inflamed paws, and slightly decreased the response induced by RB101 on inflamed paws. These results indicate that the endogenous opioid peptides, probably enkephalins, are important in the peripheral control of nociception from inflamed tissues.
Maldonado
R
R
Department of Molecular and Structural Pharmacochemistry, U266 INSERM/URA D1500 CNRS, University René Descartes, UFR of Pharmaceutical and Biological Sciences, Faculty of Pharmacy, 75270 Paris Cedex 06 France.
Valverde
O
O
Turcaud
S
S
Fournié-Zaluski
M C
MC
Roques
B P
BP
D000700:Analgesics / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D004220:Disulfides / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004745:Enkephalins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007249:Inflammation / Q000150:complications*; D007276:Injections, Intraventricular; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009270:Naloxone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D015260:Neprilysin / Q000037:antagonists & inhibitors; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement / Q000187:drug effects; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds; D051381:Rats; D017207:Rats, Sprague-Dawley
D000700:Analgesics; D004220:Disulfides; D004745:Enkephalins; D006877:Hydroxamic Acids; D009292:Narcotic Antagonists; D000644:Quaternary Ammonium Compounds; C061042:3-(N-hydroxycarboxamido-2-benzylpropanoyl)phenylalanine; C074024:RB 101; D009270:Naloxone; D010649:Phenylalanine; C041269:N-methylnaloxone; D009020:Morphine; D015260:Neprilysin